Change - Announcement of Appointment::Appointment of Dr Tan Wei Jie ("Dr Tan") as Chief Executive Officer and Executive Director

Issuer & Securities

Issuer/ Manager
AJJ MEDTECH HOLDINGS LIMITED
Securities
AJJ MEDTECH HOLDINGS LIMITED - SG0584008601 - 584
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
04-May-2026 22:25:31
Status
New
Announcement Sub Title
Appointment of Dr Tan Wei Jie ("Dr Tan") as Chief Executive Officer and Executive Director
Announcement Reference
SG260504OTHRCMBL
Submitted By (Co./ Ind. Name)
Dr Zhang Jian
Designation
Chairman and Executive Director
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr Tan Wei Jie ("Dr Tan") as Chief Executive Officer and Executive Director.

This announcement has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited ("Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST"), and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626) at 160 Robinson Road, #20-01/02, SBF Center, Singapore 068914.

Additional Details

Date of appointment
15/05/2026
Name of person
Tan Wei Jie
Age
35
Country of principal residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Board is pleased to announce the appointment of Dr Tan Wei Jie as Chief Executive Officer and Executive Director of the Company.

This appointment follows a formal evaluation process conducted by the Nominating Committee, which assessed candidates based on leadership capability, execution track record, industry alignment and long-term suitability, and has made its recommendation to the Board accordingly.

Dr Tan is a Singapore citizen and holds a Doctor of Philosophy (PhD) in Nanomedicine and Materials Science from Nanyang Technological University. Upon graduation, he joined the Group and has since undergone approximately four years of structured leadership development, taking on increasing levels of management responsibility.

During his tenure, Dr Tan has:
- secured and managed institutional contracts contributing to recurring revenue streams;
- led the Group's supply chain management (SCM) to enhance operational efficiency and cost discipline; and
- supported the alignment of commercial strategy with execution.

The Board is of the view that Dr Tan is well-positioned to lead the Group into its next phase of execution-driven growth, with a focus on operational scaling and capturing opportunities in emerging healthcare technologies, including robotics and artificial intelligence.
Whether appointment is executive, and if so, the area of responsibility
Executive. Dr Tan will be responsible for the overall management of the Group, including the execution of strategic initiatives, oversight of operational performance, and delivery of revenue growth, with a focus on translating platform capabilities into scalable and repeatable execution outcomes.
Job title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer and Executive Director
Professional qualifications
Doctor of Philosophy - Nanyang Technological University, Singapore
Bachelor of Engineering (Materials Engineering) - Nanyang Technological University, Singapore
Working experience and occupation(s) during the past 10 years
October 2021 - Present
Director of Business Development of AJJ Healthcare Management Pte. Ltd.
Shareholding interest in the listed issuer and its subsidiaries
Yes
Shareholding details
5,543,900 ordinary shares held in AJJ Medtech Holdings Limited
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Conflict of interest (including any competing business)
Nil
Undertaking (in the format set out in Appendix 7.7 or Appendix 7H) under Mainboard Rule 720(1) or Catalist Rule 720(1) has been submitted to the listed issuer
Yes
Other Principal Commitments* Including Directorships#
* "Principal Commitments" has the same meaning as defined in the Code of Corporate Governance.
# These fields are not applicable for announcements of appointments pursuant to Mainboard Rule 704(9) or Catalist Rule 704(8).
Past (for the last 5 years)
Nil
Present
Nil
Information Required
Disclose the following matters concerning an appointment of director, chief executive officer, chief financial officer, chief operating officer, general manager or other officer of equivalent rank. If the answer to any question is "yes", full details must be given.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of:-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere,
in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of director only.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.
Dr Tan will attend the mandatory training programme prescribed by the Singapore Exchange Securities Trading Limited ("SGX-ST"), which will be conducted by the Singapore Institute of Directors, within one year from the date of his appointment, to familiarise himself with the roles and responsibilities of a director of a listed issuer in Singapore.